- Home
- RCUS vs AB Comparison
RCUS vs AB Comparison
Compare RCUS & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCUS | AB |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2018 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RCUS | AB |
|---|---|---|
| Price | $28.15 | $37.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | $31.90 | ★ $40.40 |
| AVG Volume (30 Days) | ★ 1.0M | 240.6K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 8.59% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $247,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.62 | $6.45 |
| P/E Ratio | ★ N/A | $13.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.84 | $34.92 |
| 52 Week High | $31.74 | $44.11 |
Technical Indicators
Market Signals| Indicator | RCUS | AB |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 58.78 |
| Support Level | $19.78 | $37.78 |
| Resistance Level | $28.72 | $39.72 |
| Average True Range (ATR) | 1.39 | 0.55 |
| MACD | -0.20 | 0.05 |
| Stochastic Oscillator | 46.21 | 77.66 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of February 2026, the company had $880.0 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (40%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.